Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.
Aoki D, Tabata T, Yanagida S, Nakamura T, Kondo E, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Kato A, Suri A, Okamoto A, Sugiyama T. Aoki D, et al. Among authors: sugiyama t. J Gynecol Oncol. 2024 Sep;35(5):e114. doi: 10.3802/jgo.2024.35.e114. J Gynecol Oncol. 2024. PMID: 39251349 Free PMC article. Clinical Trial.
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Okamoto A, et al. Among authors: sugiyama t. J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10. J Gynecol Oncol. 2021. PMID: 33327047 Free PMC article. Clinical Trial.
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K. Katsumata N, et al. Among authors: sugiyama t. Jpn J Clin Oncol. 2008 Nov;38(11):777-85. doi: 10.1093/jjco/hyn101. Epub 2008 Oct 16. Jpn J Clin Oncol. 2008. PMID: 18927230 Free PMC article. Clinical Trial.
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T. Matoda M, et al. Among authors: sugiyama t. Gynecol Oncol. 2018 Jun;149(3):513-519. doi: 10.1016/j.ygyno.2018.04.009. Epub 2018 Apr 13. Gynecol Oncol. 2018. PMID: 29661497 Clinical Trial.
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T. Komiyama S, et al. Among authors: sugiyama t. Int J Clin Oncol. 2019 Jan;24(1):103-114. doi: 10.1007/s10147-018-1319-y. Epub 2018 Jul 20. Int J Clin Oncol. 2019. PMID: 30030657 Free PMC article.
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I. Murakami R, et al. Among authors: sugiyama t. Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8. Gynecol Oncol. 2019. PMID: 30853361 Clinical Trial.
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Kondo E, Tabata T, Suzuki N, Aoki D, Yahata H, Kotera Y, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T. Kondo E, et al. Among authors: sugiyama t. J Gynecol Oncol. 2020 Nov;31(6):e94. doi: 10.3802/jgo.2020.31.e94. J Gynecol Oncol. 2020. PMID: 33078599 Free PMC article. Clinical Trial.
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T. Motohashi T, et al. Among authors: sugiyama t. J Gynecol Oncol. 2021 Jan;32(1):e9. doi: 10.3802/jgo.2021.32.e9. Epub 2020 Nov 10. J Gynecol Oncol. 2021. PMID: 33185050 Free PMC article. Clinical Trial.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: sugiyama t. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Enomoto T, Abe M, Okamoto A, Nagasawa T, Oishi T, Nagase S, Mori M, Inokuchi Y, Kamiura S, Komiyama S, Takeshima N, Sugiyama T. Shoji T, et al. Among authors: sugiyama t. Cancer Sci. 2022 Jan;113(1):240-250. doi: 10.1111/cas.15185. Epub 2021 Nov 18. Cancer Sci. 2022. PMID: 34716979 Free PMC article. Clinical Trial.
3,905 results